RS88803A - Novel-arylsulfonamide compounds for the treatment of obesity type ii diabetes and cns-disorders - Google Patents

Novel-arylsulfonamide compounds for the treatment of obesity type ii diabetes and cns-disorders

Info

Publication number
RS88803A
RS88803A YUP-888/03A YUP88803A RS88803A RS 88803 A RS88803 A RS 88803A YU P88803 A YUP88803 A YU P88803A RS 88803 A RS88803 A RS 88803A
Authority
RS
Serbia
Prior art keywords
diabetes
disorders
treatment
cns
novel
Prior art date
Application number
YUP-888/03A
Other languages
Serbian (sr)
Inventor
Patrizia Caldirola
Ulf Bremberg
Annika Jensen
Gary Johansson
Andrew Mott
Lori Sutin
Jan Tejbrant
Original Assignee
Biovitrum Ab.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101659A external-priority patent/SE0101659D0/en
Priority claimed from SE0101660A external-priority patent/SE0101660D0/en
Priority claimed from SE0101958A external-priority patent/SE0101958D0/en
Application filed by Biovitrum Ab., filed Critical Biovitrum Ab.,
Priority claimed from PCT/SE2002/000906 external-priority patent/WO2002092585A1/en
Publication of RS88803A publication Critical patent/RS88803A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

The present invention relates to substituted bis-arylsulfonamide and arylsulfonamide compounds of the general formula (I) or the formula (II), which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.
YUP-888/03A 2001-05-11 2002-05-08 Novel-arylsulfonamide compounds for the treatment of obesity type ii diabetes and cns-disorders RS88803A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE0101659A SE0101659D0 (en) 2001-05-11 2001-05-11 New compounds
SE0101660A SE0101660D0 (en) 2001-05-11 2001-05-11 New compounds
US29413201P 2001-05-29 2001-05-29
US29410201P 2001-05-29 2001-05-29
SE0101958A SE0101958D0 (en) 2001-06-05 2001-06-05 New compounds
PCT/SE2002/000906 WO2002092585A1 (en) 2001-05-11 2002-05-08 Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders

Publications (1)

Publication Number Publication Date
RS88803A true RS88803A (en) 2007-02-05

Family

ID=43645931

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-888/03A RS88803A (en) 2001-05-11 2002-05-08 Novel-arylsulfonamide compounds for the treatment of obesity type ii diabetes and cns-disorders

Country Status (2)

Country Link
KR (1) KR100922486B1 (en)
RS (1) RS88803A (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
DE19941559A1 (en) * 1999-09-01 2001-03-15 Aventis Pharma Gmbh Use of bissulfonamides for the preparation of medicaments for the prophylaxis or treatment of hyperlipidemia

Also Published As

Publication number Publication date
KR20040007549A (en) 2004-01-24
KR100922486B1 (en) 2009-10-20

Similar Documents

Publication Publication Date Title
MXPA03010232A (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders.
MXPA03011083A (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes.
EA200600048A1 (en) BENZAZEPIN DERIVATIVES USED TO TREAT DISEASES ASSOCIATED WITH 5-HT RECEPTOR
JO2764B1 (en) Indole derivatives or benzimidazole derivatives for modulating ikappab kinase
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
DE60229530D1 (en) SUBSTITUTED PIPERAZINE AS MODULATORS OF MELANOCORTINRECEPTOR
TNSN06315A1 (en) Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
GEP20074197B (en) 5ht2c receptor modulators
MXPA04006280A (en) Spiroazacyclic compounds as monoamine receptor modulators.
UA84390C2 (en) Amide derivatives as glucokinase activators
UA83194C2 (en) Pyrimidine derivatives and their use as cb2 modulators
HK1094425A1 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
GB0222495D0 (en) Compounds
CA2449729A1 (en) Prodrugs of gaba analogs, compositions and uses thereof
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
SE0403006D0 (en) New compounds
GB0111186D0 (en) Novel compounds
AU2003260436A1 (en) Pyrimidine compounds
IL161047A0 (en) Pyrazole derivatives for increasing endogenous testosterone levels
MXPA04003910A (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension.
RS88803A (en) Novel-arylsulfonamide compounds for the treatment of obesity type ii diabetes and cns-disorders
TW200503672A (en) 2-aminobenzoyl derivatives
TW200505435A (en) Treatment of ocular disorders
WO2003105854A3 (en) Substituted dihydropyrimidines and dihydropyrimidinethiones as calcium channel blockers